Published animal pharmacokinetic measurements do not establish a human BPC-157 half-life or an effective administration schedule. The central question is what investigators measured: intact peptide, breakdown products, total radioactive label, or a clinical laboratory marker. Those measurements are not interchangeable, even when they appear in discussions of the same compound.
This review explains the best-defined animal experiment and the boundary between a formulation claim and evidence of human exposure. It does not provide dosing conversions, preparation instructions or a preferred route. The purpose is to make numerical claims easier to audit.
What pharmacokinetic measurements describe
Pharmacokinetics concerns exposure over time. Bioavailability describes how quickly and to what extent an active ingredient reaches the site where it acts. FDA's bioavailability guidance distinguishes exposure measurements from the additional clinical evidence used to evaluate safety and effectiveness. It also recognizes that locally acting preparations may need measurements other than bloodstream concentrations. FDA bioavailability guidance
This distinction prevents two opposite mistakes. Detecting a substance in blood does not by itself demonstrate a useful clinical effect. Failing to detect it in blood does not automatically prove that there was no local exposure. In either case, the assay, sampling times, detection limits and intended question determine what can be concluded.
What the rat and dog study found
He and colleagues studied BPC-157 in rats and beagle dogs using intravenous and intramuscular exposure. The reported intact-peptide elimination half-life was under 30 minutes in the tested conditions. Intramuscular absolute bioavailability differed between species, approximately 14–19% in rats and 45–51% in dogs. These are animal results, not estimates for people. Primary study, Results 2.1 and 2.2
Our interpretation is that the species difference is a reason to preserve context, not choose whichever number seems most favorable. A claim such as highly bioavailable is incomplete unless it identifies the formulation, route, species, reference exposure and measurement method. Removing those qualifiers makes a numerical statement look more portable than the experiment supports.
Why radioactivity persisted longer than intact peptide
The same paper separately tracked radioactive material in rats. Its total-radioactivity plasma half-life was about 102 hours, while metabolite analysis showed breakdown into smaller components. That number is not the half-life of intact BPC-157. The study deliberately treated these as different analyses. Primary study, Results 2.3.2 and 2.3.3
The interpretation follows the measurement: a label can remain detectable after the original molecule changes. A total-label curve therefore cannot be substituted for the intact-parent curve to claim days of active peptide exposure. It also cannot establish how long a biological effect lasts. Exposure, downstream biological response and clinical outcome are three separate questions, each requiring appropriate evidence.
What is missing for human conclusions
FDA's assessment found no human pharmacokinetic data after oral, subcutaneous, nasal or transdermal administration. It described limited rectal-study measurements below detection or quantification, not a validated human exposure profile. FDA assessment, human pharmacokinetic section
This dated finding should not be turned into a timeless claim that no relevant study could ever exist. A newer claim needs a newer primary dataset. Readers should look for a named human study, an identified assay, concentration measurements at defined times and an analysis appropriate to those measurements. A citation to animal work or to a study registration does not fill that gap.
The two-person human infusion pilot measured clinical biomarkers and vital signs, not a BPC-157 concentration-time profile. Its background half-life discussion cites the animal study; it does not supply a newly measured human half-life. We checked its full Methods and Results rather than treating that background citation as human data. Published pilot
Formulation claims require comparisons
A statement that one preparation is more stable or more bioavailable needs a defined comparator and a measurement relevant to the claim. Chemical stability during a laboratory test is not automatically absorption in a person. Absorption is not automatically symptom improvement. A shared ingredient name cannot bridge those different endpoints.
For a proposed formulation comparison, useful documentation would identify the tested preparation, analytical target, assay validation, sampling plan and uncertainty around the estimates. If the intended effect is local, the comparison must explain why its chosen measure reflects local availability. These are questions for evaluating research, not instructions for choosing or administering a preparation.
How to audit a half life claim
Before accepting a BPC-157 half-life number, identify the species, route, measured chemical entity and source table. Then ask whether the author is describing disappearance from a measured compartment or making an unsupported leap to duration of benefit. If any of those details is missing, the number is not sufficiently specified for the claimed conclusion.
The BPC-157 research overview provides the broader identity and evidence context. Serum Research is a commercial supplier. This analysis does not validate any catalog product or human-use regimen.